G007-LKtankyrase 1/2 inhibitor CAS# 1380672-07-0 |
- Cabozantinib (XL184, BMS-907351)
Catalog No.:BCC1264
CAS No.:849217-68-1
- Amuvatinib (MP-470, HPK 56)
Catalog No.:BCC2258
CAS No.:850879-09-3
- TG101209
Catalog No.:BCC2198
CAS No.:936091-14-4
- Ponatinib (AP24534)
Catalog No.:BCC2522
CAS No.:943319-70-8
- Quizartinib (AC220)
Catalog No.:BCC2548
CAS No.:950769-58-1
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1380672-07-0 | SDF | Download SDF |
| PubChem ID | 67960134 | Appearance | Powder |
| Formula | C25H16ClN7O3S | M.Wt | 529.96 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 30 mg/mL (56.61 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 4-[5-[(E)-2-[4-(2-chlorophenyl)-5-(5-methylsulfonylpyridin-2-yl)-1,2,4-triazol-3-yl]ethenyl]-1,3,4-oxadiazol-2-yl]benzonitrile | ||
| SMILES | CS(=O)(=O)C1=CN=C(C=C1)C2=NN=C(N2C3=CC=CC=C3Cl)C=CC4=NN=C(O4)C5=CC=C(C=C5)C#N | ||
| Standard InChIKey | HIWVLHPKZNBSBE-OUKQBFOZSA-N | ||
| Standard InChI | InChI=1S/C25H16ClN7O3S/c1-37(34,35)18-10-11-20(28-15-18)24-31-29-22(33(24)21-5-3-2-4-19(21)26)12-13-23-30-32-25(36-23)17-8-6-16(14-27)7-9-17/h2-13,15H,1H3/b13-12+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | G007-LK is a potent and selective inhibitor of TNKS1 and TNKS2, with IC50s of 46 nM and 25 nM, respectively.In Vitro:G007-LK is a potent inhibitor of TNKS1 and TNKS2, with IC50s of 46 nM and 25 nM, respectively, and a cellular IC50 of 50 nM. G007-LK shows no inhibition of PARP1 at doses up to 20 μM, and has a high CYP3A4 inhibition IC50 value (>25 μM)[1]. G007-LK (0-20 μM) dose-dependently inhibits hepatocellular carcinoma (HCC) cell growth. G007-LK also downregulates the levels of YAP by upregulating AMOTL1 and AMOTL2 in HCC cell lines. In addition, G007-LK (0-20 μM) synergizes with MEK and AKT inhibitors to suppress HCC cell proliferation[3].In Vivo:G007-LK displays great pharmacokinetic profile in ICR mice[1]. G007-LK (100 mg/kg chow, p.o.) significantly reduces lineage tracing from LGR5+ intestinal stem cells in mice. G007-LK (100 mg/kg chow, p.o.) specifically targets LGR5+ WNT-dependent intestinal stem cells in Lgr5-EGFP-CreERT2;R26R-tdTomato mice. G007-LK (10, 50 mg/kg, p.o.) also suppressses canonical WNT signalling. Furthermore, G007-LK (100, 1000 mg/kg chow, p.o) shows no effect on the alteration of duodenal morphology[2]. References: | |||||
G007-LK Dilution Calculator
G007-LK Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.8869 mL | 9.4347 mL | 18.8693 mL | 37.7387 mL | 47.1734 mL |
| 5 mM | 0.3774 mL | 1.8869 mL | 3.7739 mL | 7.5477 mL | 9.4347 mL |
| 10 mM | 0.1887 mL | 0.9435 mL | 1.8869 mL | 3.7739 mL | 4.7173 mL |
| 50 mM | 0.0377 mL | 0.1887 mL | 0.3774 mL | 0.7548 mL | 0.9435 mL |
| 100 mM | 0.0189 mL | 0.0943 mL | 0.1887 mL | 0.3774 mL | 0.4717 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
G007-LK is a potent and specific inhibitor of tankyrase 1/2 with IC50 values of 46 and 25 nM [1].
The telomeric repeat factor 1 (TRF1)-interacting ankyrin-related ADP-ribose polymerase 1 (tankyrase 1,TNKS1) and tankyrase 2 (TNKS2) belong to the subgroup of poly(ADP-ribosyl)ating polymerases and regulate the assembly and disassembly of large polymerized structures [1].
G007-LK is a potent and specific tankyrase 1/2 inhibitor. G007-LK reduced auto-poly-(ADP ribosy)lation of TNKS1 and TNKS2 with IC50 values of 46 nM and 25 nM, respectively. In Wnt3a-induced HEK 293 cells, G007-LK inhibited ST-Luc with IC50 value of 0.05 μM [1]. In SW480 colorectal cancer cell line transfected with GFP-TNKS1, G007-LK induces highly dynamic and mobile degradasomes containing phosphorylated beta-catenin, beta-TrCP and ubiquitin [2]. In the APC-mutant cell lines, G007-LK reduces cytosolic and nuclear β-catenin protein levels [3].
In mice bearing COLO-320DM cell xenografts, G007-LK (20 mg/kg twice daily or 40 mg/kg daily) concentration-dependently inhibited tumor growth by 61% and 48%, respectively. Also, G007-LK reduced the levels of TNKS1/2 and β-catenin, and stabilized AXIN1/2 [3].
References:
[1]. Voronkov A, Holsworth DD, Waaler J, et al. Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor. J Med Chem, 2013, 56(7): 3012-3023.
[2]. Thorvaldsen TE, Pedersen NM, Wenzel EM, et al. Structure, Dynamics and Functionality of Tankyrase Inhibitor-induced Degradasomes. Mol Cancer Res, 2015, pii: molcanres.0125.2015.
[3]. Lau T, Chan E, Callow M, et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res, 2013, 73(10): 3132-3144.
- LDK378 dihydrochloride
Catalog No.:BCC1694
CAS No.:1380575-43-8
- 2-(4-Hydroxy-2-oxoindolin-3-yl)acetonitrile
Catalog No.:BCN1575
CAS No.:1380540-77-1
- YM 750
Catalog No.:BCC7542
CAS No.:138046-43-2
- EHop-016
Catalog No.:BCC5022
CAS No.:1380432-32-5
- KML 29
Catalog No.:BCC6312
CAS No.:1380424-42-9
- Valeriandoid B
Catalog No.:BCN6754
CAS No.:1380399-57-4
- EPZ004777 HCl
Catalog No.:BCC4550
CAS No.:1380316-03-9
- EPZ5676
Catalog No.:BCC2215
CAS No.:1380288-87-8
- KB SRC 4
Catalog No.:BCC6253
CAS No.:1380088-03-8
- BET bromodomain inhibitor
Catalog No.:BCC6426
CAS No.:1380087-89-7
- Decorticasine
Catalog No.:BCN2006
CAS No.:1380-03-6
- Limonene
Catalog No.:BCN3797
CAS No.:138-86-3
- Acetylanonamine
Catalog No.:BCN2140
CAS No.:138079-62-6
- (R,R)-THC
Catalog No.:BCC7224
CAS No.:138090-06-9
- Agomelatine
Catalog No.:BCN2165
CAS No.:138112-76-2
- 7-Methoxy-1-naphthylacetonitrile
Catalog No.:BCN2242
CAS No.:138113-08-3
- H-β-HoPhe-OH
Catalog No.:BCC3240
CAS No.:138165-77-2
- (RS)-(Tetrazol-5-yl)glycine
Catalog No.:BCC6599
CAS No.:138199-51-6
- ML 289
Catalog No.:BCC6343
CAS No.:1382481-79-9
- Stearyl glycyrrhetinate
Catalog No.:BCN8486
CAS No.:13832-70-7
- Hedycoronen A
Catalog No.:BCN7653
CAS No.:1383441-73-3
- CYM 9484
Catalog No.:BCC6238
CAS No.:1383478-94-1
- BD 1008 dihydrobromide
Catalog No.:BCC6674
CAS No.:138356-09-9
- BD 1047 dihydrobromide
Catalog No.:BCC6863
CAS No.:138356-21-5
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.[Pubmed:23473363]
J Med Chem. 2013 Apr 11;56(7):3012-23.
Tankyrases 1 and 2 (TNKS1/2) are promising pharmacological biotargets with possible applications for the development of novel anticancer therapeutics. A focused structure-activity relationship study was conducted based on the tankyrase inhibitor JW74 (1). Chemical analoging of 1 improved the 1,2,4-triazole based core and led to 4-{5-[(E)-2-{4-(2-chlorophenyl)-5-[5-(methylsulfonyl)pyridin-2-yl]-4H-1,2,4-triaz ol-3-yl}ethenyl]-1,3,4-oxadiazol-2-yl}benzonitrile (G007-LK), a potent, "rule of 5" compliant and a metabolically stable TNKS1/2 inhibitor. G007-LK (66) displayed high selectivity toward tankyrases 1 and 2 with biochemical IC50 values of 46 nM and 25 nM, respectively, and a cellular IC50 value of 50 nM combined with an excellent pharmacokinetic profile in mice. The PARP domain of TNKS2 was cocrystallized with 66, and the X-ray structure was determined at 2.8 A resolution in the space group P3221. The structure revealed that 66 binds to unique structural features in the extended adenosine binding pocket which forms the structural basis for the compound's high target selectivity and specificity. Our study provides a significantly optimized compound for targeting TNKS1/2 in vitro and in vivo.
